Comorbidities in Heart Failure: How to Optimize the Treatment?
Abstract
In most patients, and particularly in elderly patients, heart failure (HF) is accompanied by a range of comorbidities that play an integral role in its progression and response to treatment. Comorbidity is defined as a chronic condition that coexists in an individual with another condition that is being described. A distinction is made between noncardiac comorbidities and cardiac conditions that are directly related to the presence of HF such as arrhythmias as well as conditions that precede and contribute to its aetiology such as hypertension, diabetes mellitus, and hyperlipidemia. In this article, we will initially focus on noncardiac comorbidities and discuss the general problem of comorbidity in HF. Then we will examine specific comorbidities and how to manage patients with HF in the best way. Finally, we will consider the problem of multidrug therapy when managing patients with comorbidities.
About the Authors
V. Chumburidze
Acad. G. Chapidze Emergency Cardiology Center
Georgia
Georgia
T. Kikalishvili
Acad. G. Chapidze Emergency Cardiology Center
Georgia
Georgia
References
1. Chong V.H., Singh J., Parry H., Saunders J., Chowdhury F., Mancini D.M., Lang C.C. Management of Noncardiac Comorbidities in Chronic Heart Failure. Cardiovasc Ther, 2015, vol. 33, no. 5, pp. 300-315. doi: 10.1111/1755-5922.12141.
2. Lang C.C., Mancini D.M. Non-cardiac comorbidities in chronic heart failure. Heart, 2007, vol. 93, no. 6, pp. 665-671.
3. Masoudi F.A., Baillie C.A., Wang Y., Bradford W.D., Steiner J.F., Havranek E.P., Foody J.M., Krumholz H.M. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998–2001. Arch Intern Med, 2005, vol. 165, no. 18, pp. 2069-2076.
4. Ather S., Chan W., Bozkurt B., Aguilar D., Ramasubbu K., Zachariah A.A., Wehrens X.H., Deswal A. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol, 2012, vol. 59, no. 11, pp. 998-1005. doi: 10.1016/j.jacc.2011.11.040.
5. Eckel R.H., Jakicic J.M., Ard J.D., de Jesus J.M., Houston M.N., Hubbard V.S., Lee I.M., Lichtenstein A.H., Loria C.M., Millen B.E., Nonas C.A., Sacks F.M., Smith S.C.Jr, Svetkey L.P., Wadden T.A., Yanovski S.Z., Kendall K.A., Morgan L.C., Trisolini M.G., Velasco G., Wnek J., Anderson J.L., Halperin J.L., Albert N.M., Bozkurt B., Brindis R.G., Curtis L.H., DeMets D., Hochman J.S., Kovacs R.J., Ohman E.M., Pressler S.J., Sellke F.W., Shen W.K., Smith S.C.Jr, Tomaselli G.F. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2014, vol. 129, no. 25, suppl 2, pp. 76-99. doi: 10.1161/01.cir.0000437740.48606.d1. Epub 2013 Nov 12.
6. Widmer F. Comorbidity in heart failure. Ther Umsch. 2011, vol. 68, no. 2, pp. 103-106. doi: 10.1024/0040-5930/a000127.
7. Triposkiadis F., Giamouzis G., Parissis J., Starling R.C., Boudoulas H., Skoularigis J., Butler J., Filippatos G. Reframing the association and significance of co-morbidities in heart failure. Eur J Heart Failure, 2016, vol. 18, pp. 744-758. doi: 10.1002/ejhf.600. Epub 2016 Jun 30.
Review
For citations:
Chumburidze V., Kikalishvili T. Comorbidities in Heart Failure: How to Optimize the Treatment? Emergency Cardiology and Cardiovascular Risks journal. 2018;2(1):280-290.
Views:
15
Email this article 